{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:00:37Z","timestamp":1793066437276,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,15]]},"DOI":"10.1093\/cid\/civ097","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T04:39:55Z","timestamp":1423629595000},"page":"1462-1471","source":"Crossref","is-referenced-by-count":371,"title":["Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)"],"prefix":"10.1093","volume":"60","author":[{"given":"Joseph","family":"Solomkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Hershberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"Popejoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Steenbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylva","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Barie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"key\n\t\t\t\t20170510134536_CIV097C1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/2047-783X-15-12-525","article-title":"Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria","volume":"15","author":"Herzog","year":"2010","journal-title":"Eur J Med Res"},{"key":"key\n\t\t\t\t20170510134536_CIV097C2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/sur.2004.5.365","article-title":"Longitudinal outcomes of intra-abdominal infection complicated by critical illness","volume":"5","author":"Barie","year":"2004","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/sur.2007.092","article-title":"Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study","volume":"10","author":"Gauzit","year":"2009","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1749-7922-9-37","article-title":"Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study","volume":"9","author":"Sartelli","year":"2014","journal-title":"World J Emerg Surg"},{"key":"key\n\t\t\t\t20170510134536_CIV097C5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170510134536_CIV097C6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/sur.2006.100","article-title":"Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections","volume":"9","author":"Edelsberg","year":"2008","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2125.2005.02443.x","article-title":"Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs","volume":"60","author":"Sturkenboom","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170510134536_CIV097C9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1017\/S0266462306051063","article-title":"Importance of appropriateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections","volume":"22","author":"Bare","year":"2006","journal-title":"Int J Technol Assess Health Care"},{"key":"key\n\t\t\t\t20170510134536_CIV097C10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","article-title":"Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock","volume":"136","author":"Kumar","year":"2009","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170510134536_CIV097C11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant beta-lactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t20170510134536_CIV097C12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C13","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170510134536_CIV097C15","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C16","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/AAC.01404-13","article-title":"In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012","volume":"57","author":"Walkty","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C17","article-title":"Activity profile of CXA-101 against gram-positive and gram-negative pathogens by broth and agar dilution","author":"Brown","year":"2008"},{"key":"key\n\t\t\t\t20170510134536_CIV097C18","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"A multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane\/tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C19","article-title":". Guidance for industry. Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t20170510134536_CIV097C20","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.06349-11","article-title":"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses","volume":"56","author":"Miller","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20170510134536_CIV097C22","article-title":"Surveillance definitions for specific types of infections","author":"Centers for Disease Control and Prevention"},{"key":"key\n\t\t\t\t20170510134536_CIV097C23","article-title":"Performance standards for antimicrobial susceptibility testing; 22nd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"key\n\t\t\t\t20170510134536_CIV097C24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00268-004-7505-2","article-title":"Source control for surgical infections","volume":"28","author":"Schein","year":"2004","journal-title":"World J Surg"},{"key":"key\n\t\t\t\t20170510134536_CIV097C25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1198\/sbr.2009.0049","article-title":"Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions","volume":"2","author":"Yan","year":"2010","journal-title":"Stat Biopharm Res"},{"key":"key\n\t\t\t\t20170510134536_CIV097C26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/(SICI)1097-0258(20000330)19:6<811::AID-SIM390>3.0.CO;2-Z","article-title":"Minimum risk weights for comparing treatments in stratified binomial trials","volume":"19","author":"Mehrotra","year":"2000","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170510134536_CIV097C27","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10\u00d7'20 progress\u2014development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170510134536_CIV097C28","article-title":"Antimicrobial resistance. Global report on surveillance","author":"World Health Organization"},{"key":"key\n\t\t\t\t20170510134536_CIV097C29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijantimicag.2012.08.013","article-title":"Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study","volume":"41","author":"De Waele","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170510134536_CIV097C30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections [Study ID numbers: 3074A1\u2013301-WW; ClinicalTrials.gov identifier: NCT00081744]","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170510134536_CIV097C31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/sur.2011.048","article-title":"Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial","volume":"13","author":"Qvist","year":"2012","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.SLA.0000048551.32606.73","article-title":"Ertapenem versus piperacillin\/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial","volume":"237","author":"Solomkin","year":"2003","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t20170510134536_CIV097C33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"key\n\t\t\t\t20170510134536_CIV097C34","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"key\n\t\t\t\t20170510134536_CIV097C35","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/CMR.00023-13","article-title":"Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M","volume":"26","author":"Woerther","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20170510134536_CIV097C37","article-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"key\n\t\t\t\t20170510134536_CIV097C38","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10096-010-1066-0","article-title":"Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008","volume":"30","author":"Hawser","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170510134536_CIV097C40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/sur.2012.084","article-title":"Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis","volume":"14","author":"Augustin","year":"2013","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20170510134536_CIV097C41","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/AAC.01808-09","article-title":"Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007\u20132008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"54","author":"Hoban","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170510134536_CIV097C42","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/60\/10\/1462\/16787398\/civ097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T20:54:15Z","timestamp":1566334455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,2,10]]},"published-print":{"date-parts":[[2015,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ097","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,10]]}}}